ReviewOncotarget2015
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
Review in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 121 citations in OpenAlex.
- Research on therapeutic clinical trials including immunotherapy in triple-negative breast cancer: a bibliometric analysis.Frontiers in oncology · 2024Pooled it
- Exploring Cutting-Edge Strategies for the Management of Triple-Negative Breast Cancer Through Drug Repurposing.Current topics in medicinal chemistry · 2026Review
- The DNA methylation landscape of primary triple-negative breast cancer.Nature communications · 2025Article
- The prognostic value of the tumor-stroma ratio compared to tumor-infiltrating lymphocytes in triple-negative breast cancer: a review.Virchows Archiv : an international journal of pathology · 2025Review
- Immunometabolic crosstalk between tumor- associated macrophages and ferroptotic cancer cells: mechanisms, regulation, and therapeutic applications.Frontiers in immunology · 2025Review
- Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance.Cell death & disease · 2024Review
- NRF2 activation by cysteine as a survival mechanism for triple-negative breast cancer cells.Oncogene · 2024Article
- Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies.Frontiers in oncology · 2024Review
- Evaluating [International journal of molecular sciences · 2023Article
- MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer.Nature communications · 2023Article
- Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features.Journal of Zhejiang University. Science. B · 2022Review
- Detection of genetic mutations in patients with breast cancer from Saudi Arabia using Ion AmpliSeq™ Cancer Hotspot Panel v.2.0.Biomedical reports · 2022Article
- Ferroptosis: A New Road towards Cancer Management.Molecules (Basel, Switzerland) · 2022Review
- Fatty acid synthetase expression in triple-negative breast cancer.Journal of pathology and translational medicine · 2022Article
- Fluid flow exposure promotes epithelial-to-mesenchymal transition and adhesion of breast cancer cells to endothelial cells.Breast cancer research : BCR · 2021Article
- Bioactive nanotherapeutic trends to combat triple negative breast cancer.Bioactive materials · 2021Review
- CRISPR/Cas9 based genome editing for targeted transcriptional control in triple-negative breast cancer.Computational and structural biotechnology journal · 2021Review
- [Molecular subtypes of urothelial carcinoma of the bladder-background and clinical relevance].Der Urologe. Ausg. A · 2021Review
- Locoregional Surgery in Metastatic Breast Cancer: Do Concomitant Metabolic Aspects Have a Role on the Management and Prognosis in this Setting?Journal of personalized medicine · 2020Review
- Drug Repurposing for Triple-Negative Breast Cancer.Journal of personalized medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Significant research has been conducted to better understand the extensive, heterogeneous molecular features of triple-negative breast cancer (TNBC). We reviewed published TNBC molecular classifications to identify major groupings that have potential for clinical trial development. With the ultimate aim to streamline translational medicine, we linked these categories of TNBC according to their gene-expression signatures, biological function, and clinical outcome. To this end, we define five potential clinically actionable groupings of TNBC: 1) basal-like TNBC with DNA-repair deficiency or growth factor pathways; 2) mesenchymal-like TNBC with epithelial-to-mesenchymal transition and cancer stem cell features; 3) immune-associated TNBC; 4) luminal/apocrine TNBC with androgen-receptor overexpression; and 5) HER2-enriched TNBC. For each defined subtype, we highlight the major biological pathways and discuss potential targeted therapies in TNBC that might abrogate disease progression. However, many of these potential targets need clinical validation by clinical trials. We have yet to know how we can enrich the targets by molecular classifications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.